<DOC>
	<DOC>NCT02475382</DOC>
	<brief_summary>The purpose of this study is to provide treatment with nivolumab, a fully human monoclonal antibody, to subjects who have relapsed after treatment with a minimum of 1 prior systemic treatment for advanced or metastatic squamous (Sq) or non-squamous (non-Sq) non-small cell lung cancer (NSCLC) , Stage IIIB/IV and whose physicians believe that nivolumab treatment is appropriate.</brief_summary>
	<brief_title>Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Sq or NonSq NSCLC, Stage IIIb/IV (histologically or cytologically confirmed) Relapsed after 1 prior platinumbased systemic treatment Eastern Cooperative Oncology Group (ECOG) Performance Status &lt; 2 CNS metastasis must be treated and returned to baseline at least 2 weeks before first dose of nivolumab and off steroids or using stable or decreasing dose of &lt; 10 mg prednisone or equivalent Prior chemotherapy, Tyrosine Kinase Inhibitor (TKI) therapy or Immunotherapy (tumor vaccine, cytokine or growth factor to control cancer) must be completed at least 2 weeks before first nivolumab dose CNS metastases (untreated and/or symptomatic) Carcinomatous meningitis ECOG Performance status &gt; 3 Corticosteroids &gt; 10 mg prednisolone/day (or equivalent) Prior treatment with antiPD1, antiPDL1, antiPDL2, antiCT137 or antiCTLA antibody, including ipilimumab or any other drugs specifically targeting T cell costimulation or checkpoint pathways</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>